Compare equities side by side
Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
Artiva Biotherapeutics is a clinical-stage biotechnology company developing off-the-shelf, allogeneic NK cell therapies for oncology indications. The company's lead candidate AB-101 is being evaluated for B-cell malignancies and solid tumors, leveraging a proprietary platform to engineer natural killer cells that can be manufactured at scale without patient-specific customization. With near-zero revenue and high cash burn, the stock trades on clinical trial readouts and partnership potential.
Artiva operates a classic clinical-stage biotech model with no current commercial revenue. The company is burning approximately $30-40M annually to advance AB-101 through Phase 1/2 trials. Value creation depends on demonstrating clinical efficacy and safety in ongoing trials, securing regulatory approvals, and either commercializing independently or partnering with established oncology players. The allogeneic (off-the-shelf) approach provides manufacturing scalability advantages versus autologous CAR-T therapies, potentially enabling lower cost-of-goods and broader patient access. Monetization pathways include outright acquisition, licensing deals with upfront/milestone payments, or eventual product sales if trials succeed.
AB-101 clinical trial data releases - objective response rates, duration of response, safety profile in B-cell malignancies
Regulatory milestone achievements - IND clearances for new indications, Phase 2 initiation timelines
Partnership announcements or M&A speculation - licensing deals with big pharma validate platform technology
Cash runway updates - quarterly burn rate and financing needs drive dilution concerns
Competitive trial results from other NK cell or allogeneic CAR-T developers affecting sector sentiment
Clinical trial failure risk - AB-101 or pipeline candidates may fail to demonstrate sufficient efficacy or acceptable safety profiles, rendering platform value near-zero
Regulatory pathway uncertainty - FDA requirements for allogeneic cell therapies continue evolving, potentially requiring larger or longer trials than anticipated
Competitive displacement - established CAR-T therapies, emerging allogeneic platforms from better-capitalized competitors (Fate Therapeutics, Celularity), or novel modalities could make NK cell approach obsolete
Well-funded competitors with similar allogeneic approaches have multi-year head starts and deeper clinical datasets
Autologous CAR-T therapies (Kymriah, Yescarta, Breyanzi) already dominate B-cell malignancy treatment, creating high efficacy bar for market entry
Large pharma in-house cell therapy programs could leverage superior manufacturing scale and commercial infrastructure
Severe cash burn ($100M+ annual operating cash outflow) with minimal revenue creates ongoing dilution risk through equity raises
Current market cap of $100M provides limited financing cushion - likely requires capital raise within 12-18 months based on burn trajectory
Negative ROE (-45.6%) and ROA (-48.6%) reflect value destruction at current stage, typical for clinical biotechs but amplifying downside risk if trials disappoint
low - Clinical trial timelines and regulatory processes are largely insulated from GDP fluctuations. However, severe recessions can impact biotech financing availability and M&A activity, affecting the company's ability to raise capital or secure partnerships. Patient enrollment may see modest impacts during economic stress, but oncology trials typically maintain priority.
Rising interest rates negatively impact valuation multiples for pre-revenue biotechs as future cash flows are discounted more heavily. Higher rates also increase the opportunity cost of holding non-yielding, high-risk equities versus bonds. Operationally, rates have minimal direct impact since the company has negligible debt (0.09 D/E ratio) and holds cash in short-duration instruments. The primary effect is through equity valuation compression and reduced access to growth capital markets.
Minimal direct credit exposure given the company operates with minimal debt and maintains high current ratio (11.65x). However, tightening credit conditions indirectly affect biotech sector funding as venture capital and crossover investors face higher hurdle rates. Reduced credit availability for potential acquirers or partners could delay strategic transactions.
growth - Attracts high-risk, high-reward biotech specialists and momentum traders betting on binary clinical catalysts. The stock appeals to investors with long time horizons (3-5+ years to potential commercialization) and tolerance for 50%+ volatility around data readouts. Value investors typically avoid given negative earnings and speculative nature. No dividend, so income investors have zero interest.
high - Clinical-stage biotechs with single-asset concentration exhibit extreme volatility. Stock can move 30-50% on trial data releases, partnership news, or sector rotation. Recent 49.5% six-month return followed by flat one-year performance illustrates boom-bust pattern. Beta likely exceeds 1.5x relative to biotech indices. Illiquidity (small market cap, limited float) amplifies price swings.